EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Post Hoc MRI Analysis of Orbital Soft Tissue Volumes Pre- and Post-Teprotumumab in Patients with Chronic, Low-Activity Thyroid Eye Disease

Shoaib Ugradar, Ada Kumar, Michael Karon, Zhenxun Wang, Prem S Subramanian, Sara T Wester

Ophthalmology and Therapy · 06.10.2026

DOI: 10.1007/s40123-026-01516-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmology and Therapy, online erschienen am 06.10.2026. Verfasst von Shoaib Ugradar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Private Practice, 9675 Brighton Way, Suite 410, Beverly Hills, CA, 90210, USA. shoaib.ugradar@gmail.com. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: A previous phase 4 trial (Chronic) evaluated teprotumumab treatment in patients with chronic, low-activity thyroid eye disease (TED). In the current study, volumetric changes in the orbital soft tissues, lacrimal glands, and full facial fat were evaluated following teprotumumab in a subset of patients from this chronic TED trial who underwent magnetic resonance imaging (MRI). METHODS: This post hoc exploratory MRI analysis examined volumetric changes of extraocular muscles (EOMs), orbital fat (OF), lacrimal glands, and full facial fat pre- and post-teprotumumab (week 24) in patients from the phase 4 Chronic trial at one preselected trial site. Patients had a TED duration of 2-10 years, diagnosis of chronic, low-activity TED (clinical activity score ≤ 1), and received eight teprotumumab infusions administered once every 3 weeks. The study (more proptotic) and fellow orbit were evaluated separately and together via MRI. RESULTS: Of the six patients (female n = 5, male n = 1) undergoing MRI at baseline and week 24, the mean age and TED duration was 45.2 and 5.5 years, respectively. At baseline, patients had a mean proptosis of 25.25 mm (study orbits) and 24.00 mm (fellow orbits). Mean (%) changes from baseline (CFB) in total EOM and OF volumes in combined study and fellow orbits after 24 weeks of teprotumumab were - 1107.3 mm3 (- 25.0%) and - 5017.1 mm3 (- 34.6%), respectively. Mean (%) CFB in full facial fat and study and fellow lacrimal gland volumes were - 12,175.9 mm3 (- 6.6%), - 116.7 mm3 (- 21.9%), and - 150.5 mm3 (- 26.4%), respectively. Proptosis response was observed in 100% (6/6) of study and 66.7% (4/6) of fellow orbits. CONCLUSION: MRI demonstrated that teprotumumab effectively reduces orbital soft tissue, facial fat, and lacrimal gland volumes in study and fellow orbits of patients with chronic, low-activity TED. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT04583735.

Schlagwörter

Stichwörter der Autor:innen

Chronic, low activityGraves’ diseaseMRIOrbitTeprotumumabThyroid eye disease

Autor:innen und Institutionen

  • Private Practice, 9675 Brighton Way, Suite 410, Beverly Hills, CA, 90210, USA. shoaib.ugradar@gmail.com.
  • Amgen Inc., Thousand Oaks, CA, USA.
  • Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, USA.
  • Department of Oculofacial Plastic Surgery, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.

Förderung

  • Amgen Inc.

Zitieren

APA

Ugradar, S., Kumar, A., Karon, M., Wang, Z., Subramanian, P. S., & Wester, S. T. (2026). Post Hoc MRI Analysis of Orbital Soft Tissue Volumes Pre- and Post-Teprotumumab in Patients with Chronic, Low-Activity Thyroid Eye Disease. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-026-01516-9

Vancouver

Ugradar S, Kumar A, Karon M, Wang Z, Subramanian PS, Wester ST. Post Hoc MRI Analysis of Orbital Soft Tissue Volumes Pre- and Post-Teprotumumab in Patients with Chronic, Low-Activity Thyroid Eye Disease. Ophthalmology and Therapy. 2026. doi:10.1007/s40123-026-01516-9

BibTeX
@article{Ugradar2026,
  author = {Ugradar, Shoaib and Kumar, Ada and Karon, Michael and Wang, Zhenxun and Subramanian, Prem S and Wester, Sara T},
  title = {Post Hoc MRI Analysis of Orbital Soft Tissue Volumes Pre- and Post-Teprotumumab in Patients with Chronic, Low-Activity Thyroid Eye Disease},
  journal = {Ophthalmology and Therapy},
  year = {2026},
  doi = {10.1007/s40123-026-01516-9}
}
Kostenlos starten →